Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians
Top Cited Papers
Open Access
- 3 December 2013
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 159 (11), 770-779
- https://doi.org/10.7326/0003-4819-159-11-201312030-00009
Abstract
This article has been corrected. The original version (PDF) is appended to this article as a supplement. The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease. This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library. Literature was reassessed in April 2013, and additional studies were included. Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events. The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease. This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system. ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease. (Grade: weak recommendation; low-quality evidence) ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease. (Grade: strong recommendation; moderate-quality evidence)This publication has 49 references indexed in Scilit:
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart FailureThe New England Journal of Medicine, 2013
- Risk of cardiac arrhythmias and conduction abnormalities in patients with acute myocardial infarction receiving packed red blood cell transfusionsJournal of Critical Care, 2011
- Characteristics and Outcomes Among Heart Failure Patients With Anemia and Renal Insufficiency With and Without Blood Transfusions (Public Discharge Data from California 2000–2006)The American Journal of Cardiology, 2011
- A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatmentKidney International, 2010
- Blood transfusion for acute decompensated heart failure—friend or foe?American Heart Journal, 2009
- Transfusion practice and outcomes in non–ST-segment elevation acute coronary syndromesAmerican Heart Journal, 2008
- Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failureEuropean Journal of Preventive Cardiology, 2008
- Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathyAmerican Heart Journal, 2008
- Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemiaAmerican Heart Journal, 2006
- Anemia as a risk factor and therapeutic target in heart failureJournal of the American College of Cardiology, 2004